Heart rate variability and cardiac arrhythmias in patients with chronic renal failure

1991 ◽  
Vol 1 (2) ◽  
pp. 131-133 ◽  
Author(s):  
B. J. Thomson ◽  
D. McAreavey ◽  
J. M. M. Neilson ◽  
R. J. Winney ◽  
D. J. Ewing
Keyword(s):  
Heart Rate ◽  
Renal Failure ◽  
Heart Rate Variability ◽  
Chronic Renal Failure ◽  
Cardiac Arrhythmias

Effects of haemodialysis on heart rate variability in chronic renal failure

1986 ◽  
Vol 46 (7) ◽  
pp. 665-670 ◽  
Author(s):  
Jari Forsström ◽  
Jorma Forsström ◽  
Esa Heinonen ◽  
Ilkka Välimäki ◽  
Kari Antila
Keyword(s):  
Heart Rate ◽  
Renal Failure ◽  
Heart Rate Variability ◽  
Chronic Renal Failure

Altered Orcadian Rhythms of Blood Pressure and Heart Rate in Non-Hemodialysis Chronic Renal Failure

1990 ◽  
Vol 7 (4) ◽  
pp. 321-327 ◽  
Author(s):  
Francesco Portaluppi ◽  
Loris Montanari ◽  
Michele Ferlini ◽  
Paolo Gilli
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Renal Failure ◽  
Chronic Renal Failure

scholarly journals Use of Ethylmethylhydroxypyridine in Patients Presenting with Myocardial Infarction: Antiischemic, Antidepressant, Anxiolytic Effects

2016 ◽  
pp. 67-74
Author(s):  
Maryna Dolzhenko ◽  
Olena Popovich ◽  
Oksana Shershnyova ◽  
Oleksandr Nudchenko ◽  
Kardo Faradzh ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Rate ◽  
Heart Rate Variability ◽  
Mental State ◽  
Cardiac Arrhythmias ◽  
Average Score ◽  
Control Group ◽  
Basic Therapy ◽  
Coronary Syndrome ◽  
St Segment

The objective: to evaluate the efficiency of ethylmethylhydroxypyridine (Mexiprim, STADA Arzneimittel AG, Germany) in patients presenting with myocardial infarction at hospital and outpatient stage. Patients and methods. The study included 59 patients with coronary artery disease, acute coronary syndrome with ST1segment elevation in the first day of admission to the ICU, AH, 3-stage, 2 degrees, HF. To all patients basic therapy according to current ESH/ESC guidelines was prescribed. To 39 patients additionally intravenous infusion of 200 mg of mexiprim o.d. for 10 days, followed by 125 mg per os three times a day for next 60 days was administered. Another 20 patients presented control group and received only basic therapy. The study design included: 24-hour Holter monitoring to estimate the dynamics of changes in the ST segment, cardiac arrhythmias and heart rate variability, evaluation by the scale of Beck, Hamilton scale for the assessment of anxiety (HARS) and depression (HDRS), the common blood and urine tests, biochemical blood analysis, evaluation of therapeutic tolerability conducted before treatment and 60 days after treatment. Surveys on a scale SAN, assessment of cognitive impairment on the MMSE scale were performed on the 60th day of treatment. Efficiency criteria were: a 50% reduction of cardiac arrhythmias, a decrease in ischemia, a decrease by 50% or more from baseline average score by HARS, HDRS scales, dynamics of the mental state questionnaire and less than 9 points on a scale of depression, reducing in SAN scale score. Results. In pаtients of mexiprim group significant reduction of depression scores by 62% were observed. According to the dynamics of the mental state questionnaire patients of mexiprim group reported feeling better, that is, reduction of score by 45% . According to the Hamilton scale for the assessment of anxiety (HARS), in particular mental anxiety – decrease in the total score of 65%, somatic anxiety – by 35.5%, and a total of 50% were revealed. In the group of patients receiving additionally intravenous Mexiprim for 10 days significantly reduced the number of single and group PACs, as well as single and multiple PVCs, not only in comparison with these parameters before the treatment, but also in comparison with the control group. In patients treated with Mexiprim no evidence of residual ischaemia were noted, but in the control group statistically significant segment depression ST remained. Heart rate variability was not significantly changed in the control group, but increased in patients who received Mexiprim. Conclusion. Use of Mexiprim in patients with myocardial infarction reduces ST segment depression, amount of ventricular and supraventricular arrhythmias, improved heart rate variability, and the state of anxiety and depression.

Effects of Orthostatism and Hemodialysis on Mean Heart Period and Fractal Heart Rate Properties of Chronic Renal Failure Patients

2017 ◽  
Vol 41 (11) ◽  
pp. 1026-1034 ◽  
Author(s):  
Juan C. Echeverría ◽  
Oscar Infante ◽  
Héctor Pérez-Grovas ◽  
Hortensia González ◽  
Marco V. José ◽  
...  
Keyword(s):  
Heart Rate ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Heart Period

A131 THE EFFECTS OF NICARDIPINE AND NITROGLYCERIN ON CARDIAC ARRHYTHMIAS AND HEART RATE VARIABILITY DURING CARDIAC SURGERY

1997 ◽  
Vol 87 (Supplement) ◽  
pp. 131A
Author(s):  
P. Liopyris ◽  
G.J. Despotis ◽  
C. McCawley ◽  
N. Skubas ◽  
C. Hogue ◽  
...  
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Cardiac Surgery ◽  
Cardiac Arrhythmias

scholarly journals Chronic baroreflex activation restores spontaneous baroreflex control and variability of heart rate in obesity-induced hypertension

2013 ◽  
Vol 305 (7) ◽  
pp. H1080-H1088 ◽  
Author(s):  
Radu Iliescu ◽  
Ionut Tudorancea ◽  
Eric D. Irwin ◽  
Thomas E. Lohmeier
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Arterial Pressure ◽  
Cardiac Arrhythmias ◽  
High Fat Diet ◽  
Renal Denervation ◽  
Gradual Increase ◽  
High Fat ◽  
Baroreflex Control ◽  
Cardiovascular Dynamic

The sensitivity of baroreflex control of heart rate is depressed in subjects with obesity hypertension, which increases the risk for cardiac arrhythmias. The mechanisms are not fully known, and there are no therapies to improve this dysfunction. To determine the cardiovascular dynamic effects of progressive increases in body weight leading to obesity and hypertension in dogs fed a high-fat diet, 24-h continuous recordings of spontaneous fluctuations in blood pressure and heart rate were analyzed in the time and frequency domains. Furthermore, we investigated whether autonomic mechanisms stimulated by chronic baroreflex activation and renal denervation—current therapies in patients with resistant hypertension, who are commonly obese—restore cardiovascular dynamic control. Increases in body weight to ∼150% of control led to a gradual increase in mean arterial pressure to 17 ± 3 mmHg above control (100 ± 2 mmHg) after 4 wk on the high-fat diet. In contrast to the gradual increase in arterial pressure, tachycardia, attenuated chronotropic baroreflex responses, and reduced heart rate variability were manifest within 1–4 days on high-fat intake, reaching 130 ± 4 beats per minute (bpm) (control = 86 ± 3 bpm) and ∼45% and <20%, respectively, of control levels. Subsequently, both baroreflex activation and renal denervation abolished the hypertension. However, only baroreflex activation effectively attenuated the tachycardia and restored cardiac baroreflex sensitivity and heart rate variability. These findings suggest that baroreflex activation therapy may reduce the risk factors for cardiac arrhythmias as well as lower arterial pressure.

Sign in / Sign up

Export Citation Format

Share Document